2024 · GS Paper 4 · Q12 · 20 marks

Dr. Srinivasan is a senior scientist working for a reputed biotechnology company known for its cutting-edge research in pharmaceuticals. Dr. Srinivasan is heading a research team working on a new drug aimed at treating a rapidly spreading variant of a new viral infectious disease. The disease has been rapidly spreading across the world and the cases reported in the country are increasing. There is huge pressure on Dr. Srinivasan's team to expedite the trials for the drug as there is significant market for it, and the company wants to get the first-mover advantage in the market. During a team meeting, some senior team members suggest some shortcut for expediting the clinical trials for the drug and for getting the requisite approvals. These include manipulating data to exclude some negative outcomes and selectively reporting positive results, foregoing the process of informed consent and using compounds already patented by a rival company, rather than developing one's own component. Dr. Srinivasan is not comfortable taking such shortcuts, at the same time he realises meeting the targets is impossible without using these means. (a) What would you do in such a situation? (b) Examine your options and consequences in the light of the ethical questions involved. (c) How can data ethics and drug ethics save humanity at large in such a scenario?

In short

Dr. Srinivasan should refuse the shortcuts on record and pursue honest, consented trials on a regulatory fast track with a licensed compound. Ranbaxy's 2013 guilty plea and 500-million-dollar penalty in the US over falsified data shows what the shortcut option costs.

Model answer

Ghissu Editorial · Verified 4 Oct 2026

Introduction
Dr. Srinivasan must decide whether pandemic urgency and first-mover pressure can justify faking data, skipping consent and using a rival's patented compound.
(a) What I Would Do
•

Refuse on record

Minute the objection, practising Documented Continuation.

•

Lawful speed

Seek accelerated approval from CDSCO under the New Drugs and Clinical Trials Rules, 2019, and license the rival's compound, as Merck did for molnupiravir in 2021 [current event].

(b) Options and Consequences in the Light of Ethical Questions
The core dilemma is between Speed of Access for Patients and Scientific Integrity.
•

(i) CAPITULATE [Procedural-Evasive]

Adopting the shortcuts invites Moral Myopia and a Ranbaxy-style collapse; Ranbaxy [case] paid 500 million dollars in the US in 2013 over false data.

•

(ii) CONFRONT [Strict-Legal]

Going straight to the media is a Lone-Rebel Reading that halts the trial.

•

(iii) EVADE [Empathetic-Humanitarian]

Untested compassionate release is Motivated Blindness.

•

(iv) COMPROMISE [Compromised-Hybrid]

Honest data with the rival's compound is Dual-Standard Practice.

•

(v) RECONCILE ✓ [Balanced]

Honest, consented trials on a fast track with a licensed compound (recommended).

Justification:
Kant's Categorical Imperative: patients are ends, never means.
(c) How Data Ethics and Drug Ethics Save Humanity
•

Trust

Thalidomide harmed over 10,000 children; honest data prevents a repeat.

•

Consent

Swasthya Adhikar Manch (2013) [case] brought audio-visual consent to Indian trials.

•

Shared science

The SARS-CoV-2 genome, shared in January 2020, let vaccine design begin within days.

Conclusion
A fast drug that fails costs more lives than a slow one that works; integrity with urgency is the only ethical speed.

This model answer is indicative and the model can make mistakes; please verify key facts independently.

Hand-drawn diagram: Speed vs Scientific Integrity. Speed vs Scientific Integrity. Venn diagram: Speed to Patients, Scientific Integrity; overlap: Honest trial on a fast track
Diagram: Speed vs Scientific Integrity

Practise this question

  1. 1Get the answer sheet

    Sized for this question.

  2. 2Write your answer

    Timed, by hand.

  3. 3Get it marked

    Your score and what to fix.

Share this questionWhatsAppTelegramXLinkedIn

This chapter in the exam

Emerging Domain Dilemmas4 questions

Asked in 3 of 14 sittings since 2013

2013
–
2014
–
2015
–
2016
–
2017
–
2018
1
2019
–
2020
–
2021
–
2022
–
2023
1
2024
2
2025
–
2026
–

All 4 questions, sorted by sub-topic, with model answers and practice.

Question from the official UPSC Civil Services (Main) Examination 2024 paper. Answer written by Ghissu's engine and checked against our editorial standards. Found an error? Tell us and we correct it within 48 hours.

Ghissu

OUTWORK·
OUTTHINK·
MASTER THE SYSTEM·
OUTWORK·
OUTTHINK·
MASTER THE SYSTEM·
OUTWORK·
OUTTHINK·
MASTER THE SYSTEM·
OUTWORK·
OUTTHINK·
MASTER THE SYSTEM·
OUTWORK·
OUTTHINK·
MASTER THE SYSTEM·
OUTWORK·
OUTTHINK·
MASTER THE SYSTEM·
OUTWORK·
OUTTHINK·
MASTER THE SYSTEM·
OUTWORK·
OUTTHINK·
MASTER THE SYSTEM·